News Releases

June 4, 2024

Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2024

Apollomics Announces Presentation at the 2024 BIO International Convention

May 8, 2024

Apollomics Announces Private Placement Financing and Addition to Board of Directors

April 25, 2024

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

April 10, 2024

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

April 2, 2024

Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 28, 2024

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

March 26, 2024

Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

March 4, 2024

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer

February 7, 2024

Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference